Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review.       

Sections:  u.s.   
Topics:  New Jersey   Camden County   Cherry Hll   
RELATED ARTICLES
BING NEWS:
  • Eisai, Biogen launch Leqembi in South Korea
    Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has ...
    11/27/2024 - 2:56 pm | View Link
  • Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
    Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending ...
    11/15/2024 - 1:04 am | View Link
  • Eisai wins over European regulators on Alzheimer’s drug Leqembi
    The EMA sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.
    11/14/2024 - 8:21 am | View Link
  • EMA committee rethinks stance and recommends Leqembi for Alzheimer’s disease
    Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.
    11/14/2024 - 6:34 am | View Link
  • EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
    The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with early Alzheimer's disease, reversing its initial decision from four months ...
    11/14/2024 - 5:31 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More U.s. News